BioCentury | May 11, 2019
Product Development

Now grown up, independent biotechs bulk up their platforms with more modalities

As the incoming class of independent biotechs look to build on their clinical and commercial successes, a handful are expanding beyond the technology that got them there, bringing in new modalities to complement their platforms...
BC Week In Review | Jun 1, 2018
Financial News

Kiniksa upsizes IPO, raises $152.6M

Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA) raised $152.6 million on May 23 through the sale of 8.5 million shares at $18 in an upsized IPO underwritten by Goldman Sachs, J.P. Morgan, JMP Securities and Wedbush. Kiniksa priced...
BC Extra | May 24, 2018
Financial News

Kiniksa upsizes IPO, raises $152.6M

Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA) gained $1.47 to $19.47 Thursday after raising $152.6 million through the sale of 8.5 million shares at $18 in an upsized IPO underwritten by Goldman Sachs, J.P. Morgan, JMP Securities and...
BC Week In Review | May 18, 2018
Financial News

Kiniksa, Scholar Rock set IPO price ranges

Kiniksa Pharmaceuticals Ltd. (Hamilton, Bermuda) and Scholar Rock Holding Corp. (Cambridge, Mass.) each set price ranges on May 14 for their respective NASDAQ IPOs. Kiniksa now plans to sell 7 million shares at $17 to...
BC Extra | May 14, 2018
Financial News

Kiniksa, Scholar Rock set IPO price ranges

Kiniksa Pharmaceuticals Ltd. (Hamilton, Bermuda) and Scholar Rock Holding Corp. (Cambridge, Mass.) each set price ranges on Monday for their respective NASDAQ IPOs. Kiniksa now plans to sell 7 million shares at $17 to $19...
BC Week In Review | May 4, 2018
Financial News

Ex-Synageva team planning Kiniksa IPO

Kiniksa Pharmaceuticals Ltd. (Hamilton, Bermuda) filed on April 27 to raise up to $100 million in an IPO on NASDAQ underwritten by Goldman Sachs, J.P. Morgan, JMP Securities and Wedbush PacGrow. Kiniksa Chairman and CEO...
BC Extra | Apr 28, 2018
Financial News

Ex-Synageva team planning Kiniksa IPO

Kiniksa Pharmaceuticals Ltd. (Hamilton, Bermuda) filed to raise up to $100 million in an IPO on NASDAQ underwritten by Goldman Sachs, J.P. Morgan, JMP Securities and Wedbush PacGrow. Kiniksa Chairman and CEO Sanj Patel, President...
BioCentury | Dec 2, 2017
Strategy

Branching out

Decibel Therapeutics Inc. and Regeneron Pharmaceuticals Inc. have embarked on a deal that gives the smaller company a suite of technologies it could not build itself, while giving the big cap a stake in a...
BioCentury | Apr 15, 2017
Strategy

WAC-a-mol

While investors, media and even some payers have been touting the pricing of three recently launched drugs as sensible, it is not clear whether the lower-than-expected list prices will actually reduce costs to payers. But...
BC Innovations | Apr 6, 2017
Targets & Mechanisms

Competing for growth

With little in the clinical pipeline for achondroplasia beyond BioMarin Pharmaceutical Inc. ’s late-stage vosoritide, startups Therachon AG and BioClin Therapeutics Inc. are rethinking how to tackle the disease. By targeting FGFR3 directly, the two...
Items per page:
1 - 10 of 150